New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine ...Middle East

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant reductions compared to placebo in mean monthly migraine days (MMDs) within the first 4 weeks, in...

Read More Details
Finally We wish PressBee provided you with enough information of ( New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine )

Also on site :

• 'Hissing door mid-air': AI flight to Hong Kong spooks flyers; crew use napkins to 'fix' issue
• Prabowo hails BRICS entry, reaffirms Indonesia’s non-aligned stance
• Israel-Iran war stretches into a second week without diplomatic breakthrough